Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.

作者信息

Shubrook Jay H

机构信息

Professor, Primary Care Department, Director of Clinical Research and Diabetes Services, Touro University, California College of Osteopathic Medicine, Vallejo, California, USA.

出版信息

J Fam Pract. 2018 Aug;67(8 suppl):S49-S54.

PMID:30137054

Abstract

摘要

相似文献

Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.

J Fam Pract. 2018 Aug;67(8 suppl):S49-S54.

Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.

J Fam Pract. 2017 Oct;66(10 Suppl):S17-S28.

Retrospective analysis of liraglutide and basal insulin combination therapy in Japanese type 2 diabetes patients: The association between remaining β-cell function and the achievement of the glycated hemoglobin target 1 year after initiation.

J Diabetes Investig. 2018 Jul;9(4):822-830. doi: 10.1111/jdi.12773. Epub 2017 Dec 13.

Surpassing insulin glargine in type 2 diabetes with tirzepatide.

Lancet. 2021 Nov 13;398(10313):1779-1781. doi: 10.1016/S0140-6736(21)02279-0. Epub 2021 Oct 18.

Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling.

Postgrad Med. 2020 Nov;132(8):663-666. doi: 10.1080/00325481.2020.1809906. Epub 2020 Oct 19.

Combination therapy of glucagon-like peptide-1 receptor agonists and insulin for patients who developed diabetes after partial pancreatectomy.

J Diabetes Investig. 2016 May;7(3):381-5. doi: 10.1111/jdi.12423. Epub 2015 Oct 14.

[Starting insulin or not? And if so, which basal insulin?].

Ned Tijdschr Geneeskd. 2020 Sep 24;164:D4583.

A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus.

Postgrad Med. 2014 May;126(3):135-44. doi: 10.3810/pgm.2014.05.2763.

Canagliflozin as a replacement therapy for patients with type 2 diabetes not responding to GLP-1 receptor agonists.

Diabetes Metab. 2017 Sep;43(4):373-374. doi: 10.1016/j.diabet.2017.03.007. Epub 2017 May 2.

Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial.

Diabetes Obes Metab. 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验